Evidence map›Paper›PMID 37956396›Full record

ArticleJapanese journal of clinical oncology2024

Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor.

Risa Akahira, Koji Fukuda, Kazuhiro Shimazu, Taichi Yoshida, Daiki Taguchi, Hanae Shinozaki, Hiroshi Nanjyo, Hiroyuki Shibata

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Risa AkahiraDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.
Koji FukudaDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.
Kazuhiro ShimazuDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.
Taichi YoshidaDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.
Daiki TaguchiDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.
Hanae ShinozakiDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.
Hiroshi NanjyoDepartment of Pathology, Akita University Hospital, Akita, Japan.
Hiroyuki ShibataDepartment of Clinical Oncology, Graduaste School of Medicine, Akita University, Akita, Japan.ORCID 0000-0003-3581-3506
Akita University · JPAkita University Hospital · JP

Funding

Operating Expenses of Department of Clinicaloncology
6 · The paper itself

Abstract

Pancreatic cancer is a malignancy with a high mortality rate, accounting for 37 000 people annually in Japan. It is rarely diagnosed in a resectable state, and effective medicines for its advanced stage are scarce. Some pancreatic cancer is hereditary, and ~10% have germline mutations of Breast cancer 1/2 (BRCA1/2). BRCA1/2 are key molecules involved in homologous recombination to repair DNA double-strand break. Platinum-based drugs and poly Adenosine diphosphate ribose (ADP) ribose polymerase inhibitors that induce synthetic lethality would be theoretically effective in patients with loss-of-function mutations in BRCA1/2. Strictly speaking, some discrepancy between the pathogenicity of BRCA1/2 and their drug sensitivity might be expected. Hence, we report that platinum-based anticancer agents and poly ADP ribose polymerase inhibitors were effective against pancreatic cancer bearing BRCA2 p.I3169M fs*48.

Indexed as

Antineoplastic AgentsPancreatic NeoplasmsBRCA1 ProteinBRCA2 ProteinGerm CellsGerm-Line MutationHumansPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsBRCA2 p.I3169M fs*48HBOC syndromehomologous recombination deficiencypancreatic cancerPARP inhibitor

Identifiers

PMID37956396
PMCPMC10849180
OpenAlexW4388621677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.